CS2009 + oxaliplatin

CS2009 + oxaliplatin is a combination drug comprised of the investigational agent CS2009 and the established platinum-based chemotherapy oxaliplatin. Oxaliplatin is a platinum alkylating agent that forms DNA adducts, blocking DNA replication and transcription, resulting in cytotoxicity and cell death in proliferating cells[2][1]. The mechanism of action for CS2009 is not specified in the provided data, and its pharmacology, target, developer, and clinical status remain unclear. The combination is presumed intended for anticancer applications, exploiting oxaliplatin's broad spectrum activity and synergy with other agents in solid tumors, especially colorectal cancer[1].